Quisinostat (USAN;[2] development code JNJ-26481585) is an experimental drug candidate for the treatment of cancer.

It is a "second generation" histone deacetylase inhibitor with antineoplastic activity.

[6] It was developed by Janssen Pharmaceuticals and licensed to NewVac LLC.

[7] Preclinical studies show that quisinostat amplifies HDAC-repressed expression of E-cadherin, leading to a reversal of epithelial to mesenchymal transition in tumor cells.

[7] Results of a phase I trials in patients with multiple myeloma in combination with bortezomib and dexamethasone were published in 2016.